Peptomyc S.L. benefits from the expertise of a strong Scientific Advisory Board (SAB) comprising the following internationally renowned thought leaders in oncology:

Josep Tabernero


Head of the Medical Oncology Department of the Vall d’Hebron University Hospital; Director of the Vall d’Hebron Institute of Oncology, Barcelona, Spain.


Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently Head of the Medical Oncology Department at the Vall d’Hebron Barcelona Hospital Campus, Director of the Vall d’Hebron Institute of Oncology (VHIO), and leads the Research Innovation of Catalonian Cancer Centers Network.

He also directs VHIO´s Gastrointestinal and Endocrine Tumors Group, the Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”, and is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with molecular targeted therapies, with particular emphasis on EGFR-family inhibitors and IGFR-PI3K-Akt-mTOR pathway inhibitors, as well as phase II and III studies with novel chemotherapeutics.

Based on the idea that each tumor has an independent genetic identity, his group aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation. One of his team´s main objectives is to establish novel predictive markers of response to anti-cancer therapies and identify markers of primary resistance (de novo) and secondary treatment.

At preclinical level, in collaboration with VHIO´s cancer researchers and physician-scientists, he develops new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study tumor development in optimal research models. He also leads research into the study of circulating biomarkers (detection and genotyping of circulating free DNA), and is dedicated to advancing the immuno-oncology field through a large portfolio of trials with some of the most promising targets in immune checkpoints and cytokines. By paring immune therapeutics with oncogenomics, his team seeks to render anti-cancer therapies more precise.

Dr. Tabernero serves on the Editorial Boards of various top tier journals includingAnnals of Oncology, ESMO Open, Cancer Discovery andClinical Cancer Research. He has (co) authored approximately 350 peer-reviewed papers.

He is currently President (2018 – 2019) of the European Society for Medical Oncology´s (ESMO), and also serves as member of its Executive Board. He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and has been appointed as member of several Educational and Scientific Committees of ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.

back to top

Roger Stupp


Chief of Neuro-oncology in the Department of Neurology, Northwestern Medicine, Feinberg School of Medicine
Professor of Neurological Surgery, Neurology, and Oncology, Northwestern University Feinberg School of Medicine
Co-Director, Northwestern Brain Tumor Institute
Associate Director for Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago Illinois

Roger Stupp trained in Internal Medicine, Oncology/Hematology in Switzerland and at the University of Chicago. He worked over 17 years as a physician and researcher at the University of Lausanne, before being appointed in 2013 as the Director of the Department of Oncology and Cancer Center at the University Hospital in Zurich, Switzerland. He moved in 2017 to take up his current positions at Northwestern University in Chicago. He has been a member of the European Organization for Research and Treatment of Cancer (EORTC) since 1994, and serves as the President of the organization since 2012. Dr. Stupp’s research focuses on early drug development, the combination of chemo- and radiotherapy, multidisciplinary cancer management, namely in the areas of lung cancer and brain tumors. He is involved in bringing innovative and multimodal treatments to the clinic. Roger Stupp has been the principal investigator for large multimodality clinical trials in brain tumors and non-small cell lung cancer.

Dr. Stupp is section editor for the European Journal of Cancer. He serves in scientific or educational committees of the European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO); he also acts as a consultant for several European and National funding agencies.

back to top

Enriqueta Felip

Head of the Thoracic Cancer and the Head and Neck Cancer Units within the Oncology Department of Vall d’Hebron University Hospital, Barcelona, Spain


Enriqueta Felip is Head of the Thoracic Cancer and the Head and Neck Cancer Units within the Oncology Department of Vall d’Hebron University Hospital, Barcelona, Spain. She is also Associate Professor at the Autonomous University of Barcelona (UAB). Enriqueta Felip received her medical degree from the UAB, where she also completed her PhD studies in medical oncology.

Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. Current research lines include the individualization of chemotherapy in early-stage disease, the use of pharmacogenomic approaches, the evaluation of new drugs, and the optimization of immunotherapy strategies.

She is currently a member of the Spanish Lung Cancer Group (SLCG), the Spanish Society of Medical Oncology (SEOM), the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC) and the National Lung Cancer Partnership. She is the coordinator of the lung cancer program of the European School of Oncology (ESO). Dr Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.

back to top

Aleix Prat, MD PhD

Head of Medical Oncology Department, Hospital Clínic, Barcelona Associate Professor, University of Barcelona Head of Translational Genomics and Targeted Therapeutics Group, IDIBAPS

Dr. Aleix Prat is currently Head of the Medical Oncology Department of Hospital Clínic in Barcelona (Spain), Associate Professor of the University of Barcelona and Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS). He obtained his MD degree in 2003 from the University of Barcelona and completed a medical oncology fellowship in 2008 at Vall d´Hebron Institute of Oncology (VHIO). In 2008, Dr Prat became a postdoctoral research associate at the Lineberger Comprehensive Cancer Center (University of North Carolina at Chapel Hill, USA) in the Laboratory of Prof. Charles M. Perou.

In 2012, he returned to Barcelona as Head of the Translational Genomics Group at VHIO and in 2014, he moved to Hospital Clínic and IDIBAPS. Dr. Prat is a clinical scientist with a longstanding research interest in the clinical application of laboratory findings in cancer, with a particular interest in gene expression and the clinical implications of different intrinsic molecular subtypes of breast cancer. He designs and leads clinical trials of novel drugs and approaches using molecular-based biomarkers, and is currently the chair of SOLTI, an academic cooperative group with more than 90 hospitals and 300 members across Spain, Portugal and Italy. In addition, he is a member of the executive board of the Breast International Group (BIG). Since 2007, he has actively taken part in a total of 133 publications (H-score of 45), with a total of 12741 citations and 95 communications in international conferences.

back to top

Alain Thibault

Dr. Thibault is an expert in oncology drug development. He has led clinical programs of chemotherapy, molecularly targeted therapy and biologics in solid tumors and haematological malignancies from the translational and entry-into-man stages to IPO, both in the EU and the US. He was most recently focused on immuno-oncology development targeting co-stimulatory receptors and modification of the tumor micro-environment. His regulatory experience ranges from IND/IMPD-CTA to drug approvals in oncology and rare diseases. Dr. Thibault received his Medical Oncology certification from the National Cancer Institute, USA and his Medicine Doctorate from McGill University, Canada.

back to top

Alfredo Covelli

Dr. Alfredo Covelli was trained as a medical oncologist at the Department of Neoplastic Disease, Mount Sinai Hospital, New York. Before joining the pharma industry, he held academy positions at Institute of Medical Pathology, School of Medicine, University “Federico I” in Naples, and at the Division of Hematology, School of Medicine, University “La Sapienza” in Rome. Over the last 30 years, he held a variety of Global and Country Management positions in the pharma industry, both in Clinical Research and in Commercial Operations in Italy, France, Switzerland and the US (Farmitalia, Pierre Fabre, Sandoz, and Aventis). In his last position, he served as Vice President and Head, Clinical Research and Medical Affairs, Region Europe, Novartis Oncology. He is now a consultant to various Biotech Companies in developing innovative therapies in oncology.

back to top